PI3K inhibitors and their role as novel agents for targeted therapy in lymphoma
V Sapon-Cousineau, S Sapon-Cousineau… - … Treatment Options in …, 2020 - Springer
Opinion statement Phosphatidylinositol 3-kinase (PI3K) inhibitors represent a novel class of
agents targeting the key cellular regulatory PI3K/AKT/mTOR pathway involved in crucial …
agents targeting the key cellular regulatory PI3K/AKT/mTOR pathway involved in crucial …
[HTML][HTML] Allogeneic hematopoietic stem cell transplant infusion during venovenous extracorporeal membrane oxygenation support
…, N Assanangkornchai, V Sapon-Cousineau… - Critical Care …, 2021 - journals.lww.com
BACKGROUND: Management of hematopoietic stem cell transplant complicated by respiratory
failure has been facilitated by the use of extracorporeal membrane oxygenation as a …
failure has been facilitated by the use of extracorporeal membrane oxygenation as a …
[HTML][HTML] Hemolytic anemia in a 26-year-old woman with vomiting and fatigue
M Elharram, V Sapon-Cousineau, V Tagalakis - CMAJ, 2018 - Can Med Assoc
The answer is both (a) and (e). Both microangiopathic anemia and cobalamin (vitamin B12)
deficiency should be considered. Although our patient was originally from Sub-Saharan …
deficiency should be considered. Although our patient was originally from Sub-Saharan …
Jejunal mucormycosis in a patient with refractory AML
S De l'Etoile-Morel, V Sapon-Cousineau, M Sebag… - Authorea …, 2021 - techrxiv.org
… Samuel De l’Etoile-Morel1, Vladimir Sapon-Cousineau1, Michael Sebag1, Zu-hua Gao1, …
Vladimir Sapon-Cousineau, MD. Department of Medicine, Division of Hematology. 1001 …
Vladimir Sapon-Cousineau, MD. Department of Medicine, Division of Hematology. 1001 …
[HTML][HTML] Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment
I Brana, LL Siu - BMC medicine, 2012 - Springer
The phosphatidylinositol 3-kinase (PI3K) pathway is commonly deregulated in cancer. In
recent years, the results of the first phase I clinical trials with PI3K inhibitors have become …
recent years, the results of the first phase I clinical trials with PI3K inhibitors have become …
[HTML][HTML] Clinical development of phosphatidylinositol 3-kinase inhibitors for non-Hodgkin lymphoma
X Fang, X Zhou, X Wang - Biomarker research, 2013 - Springer
Phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling
pathway is extensively explored in cancers. It functions as an important regulator of cell …
pathway is extensively explored in cancers. It functions as an important regulator of cell …